Swiss-American eye specialist Alcon (NYSE: ALC) has announced positive top-line results from two Phase III trials evaluating the efficacy and safety of AR-15512.
The COMET-2 and COMET-3 studies are assessing the novel therapy, a TRPM8 agonist, for the signs and symptoms of dry eye disease.
Both trials met the primary efficacy endpoint, a commonly-used metric evaluating tear production, which the firm said was consistent with the proposed mechanism of action.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze